Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvs.2010.12.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Department of Population and Quantitative Health Sciences, Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA.
Background: Mosaic loss of the Y chromosome (LOY) is a somatic, age-related event that has been previously associated with a variety of diseases of aging. A prior study of European cohorts demonstrated an association between LOY and Alzheimer's Disease and more recent molecular studies have shown that LOY can also occur within microglia, suggesting a potential functional role in AD pathogenesis.
Method: In this study, we further validate the association between LOY in blood and AD via prospective analyses of 1,447 males.
Clinical Manifestations.
Alzheimers Dement
December 2024
Department of Neurology, Harvard Medical School, Boston, MA, USA.
Background: Cognitive tests of naming ability have been shown to have diagnostic and prognostic utility in both mild cognitive impairment (MCI) and Alzheimer's disease (AD; Taler & Phillips, 2008). The Boston Naming Test (BNT) is the most common naming test, which consists of 60 black-and-white drawings and takes 20-30 minutes to administer. Retrospective analysis has shown that administering the BNT in an adaptive fashion could result in a comparable measure of the patient's naming ability in only 8 items instead of 60.
View Article and Find Full Text PDFBackground: Cognitive dysfunction is central to clinicopathological models of Alzheimer's disease (AD). While AD prospective studies assess similar cognitive domains, the neuropsychological tests used vary between studies, limiting potential for aggregation. We examined a machine learning (ML) data harmonisation method for neuropsychological test data to develop a harmonised PACC score for the Alzheimer's Dementia Onset and Progression in International Cohorts (ADOPIC) consortium.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Queen Mary University of London, London, United Kingdom.
Background: Alzheimer's disease (AD) is associated with a range of non-cognitive symptoms that can be early or even presenting features. Better recognition of pre-diagnostic symptoms of AD would support improved early detection and diagnosis.
Method: To identify possible prodromal symptoms of AD, we systematically searched three electronic databases for prospective longitudinal studies to March 2023, that reported the risk of AD diagnosis associated with non-cognitive symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!